Press releases

Release
23.02.2018

2018 financial communication calendar

Download
Release
31.01.2018

Half-year report of the liquidity contract with PORTZAMPARC, with increased liquidity

Download
Release
22.01.2018

VALBIOTIS announces a significant effect of VALEDIA® on intestinal microbiota

Download
Release
08.01.2018

VALBIOTIS invited to participate in annual J.P. Morgan Healthcare conference

Download
Release
06.12.2017

Positive preclinical results for the active ingredient in VAL-63-NAFLD on non-alcoholic fatty liver, a risk factor for NASH

Download
Release
04.12.2017

Metformin + TOTUM-63 combination: first positive preclinical data for possible use in diabetes real life practice

Download
Release
08.11.2017

VALEDIA®: launch of “pivotal” REVERSE-IT clinical trial to obtain a health claim

Download
Release
16.10.2017

LIPIDRIVE®: efficacy confirmed in three models, finalization of recruitment for Phase I/II in humans

Download
Release
29.09.2017

Consolidated results for the first half of 2017

Download